Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

This study observed that baricitinib led to significant hair regrowth and improved psychological well-being in severe alopecia areata patients over 48 weeks, with 63.2% achieving a SALT score of ≤20.

This study found that Agaricus bisporus-derived β-Glucan particles showed potential as an anticancer, antimicrobial, and antioxidant agent, inducing apoptosis and disrupting mitochondrial membrane potential in cervical cancer HeLa cells.

This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.

This review discusses the development and potential therapeutic applications of adenosine receptor agonists and positive allosteric modulators, noting that while many clinical trials have been unsuccessful, initial results for new compounds are promising.

This article reviews the empirical use of algae in traditional remedies and highlights the need for scientific understanding of algae's bioactive compounds used in cosmetics without providing new experimental results.

This study did not find any correlation or linkage disequilibrium between androgen receptor gene CAG/GGC haplotypes and androgenetic alopecia in Mexican brothers.

This study reports no new findings but provides corrected figures for the long-term safety and efficacy of ritlecitinib in treating alopecia areata from the ALLEGRO-LT phase 3 study.

This review discusses the regulatory roles of type 2 alarmin cytokines in skin immunity, focusing on their implications in host defense, chronic inflammation, and cancer, but reports no new clinical results.

This study found that α-ketoglutarate protected dermal papilla cells from oxidative stress by enhancing the Nrf2 pathway and mitigating cell damage through the ERK/Nrf2 axis.

This study presents the first documented case of a woman with Alström syndrome successfully conceiving and giving birth, highlighting the importance of managing systemic comorbidities during pregnancy.

In this study, baricitinib treatment over an average of 18.5 months resulted in a 72% reduction in alopecia severity scores among patients aged 65 or older, with mild adverse effects and no severe complications reported.

In this study, patients with severe alopecia areata who were treated with baricitinib 4 mg/day for 48 weeks showed significant improvements in both hair regrowth and nail abnormalities, although the correlation between hair and nail improvement was weak.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

This case report highlights the successful treatment of a 37-year-old male with steroid-resistant beard alopecia areata using baricitinib, a JAK-1/2 inhibitor, over 9 months, resulting in reduced hair loss and improved hair density.

Arg1+ macrophages may play a role in causing alopecia areata.

This article is a letter to the editor regarding a case of alopecia areata with polymyalgia rheumatica and does not report new clinical results.

This study developed a handheld card to simplify the calculation of the SALT score for assessing alopecia areata severity, noting that while it accelerates the process, formal validation against existing methods is still needed.

In this study, baricitinib showed promising results in improving scalp, eyebrow, and eyelash hair loss in adults with severe and very severe alopecia areata over 52 weeks.

This study found no correlation between lipid markers and androgenetic alopecia severity, but noted a potential link between lower HDL levels and more severe alopecia in women.

This study analyzed online discussions and search behavior in Gulf countries, uncovering significant engagement and identifying gaps in awareness and understanding of alopecia areata among patients and healthcare professionals, suggesting a need for targeted educational initiatives to enhance support and reduce stigma.

This review describes the clinical presentation, diagnosis, and management of adrenomyeloneuropathy, including rehabilitative therapies and spasticity management, and reports no new clinical results.

This report presents the first documented case of CARASIL in an Arabic patient and notes unique magnetic resonance spectroscopy findings compared to prior cases.

This study reported unexpected positive results in two males with androgenetic alopecia using a cyclodextrin-enabled, natural-based formula over 270 days, showing marked hair thickening and reduced scalp hair loss.

This case study reports a rare instance of both alopecia areata and fixed drug eruption occurring in the same area on a 40-year-old man's beard, triggered by oral paracetamol, highlighting potential shared pathogenic pathways and the isotopic phenomenon.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

In this study, the alcoholic extract of Eclipta alba demonstrated significant anticancer activity in vitro by inducing apoptosis in breast cancer cell lines and showed strong antioxidant properties.